Chinese pharma intermediates may become uncompetitive compared to India: Ashwin Shroff, Excel Industries Ltd

Interview with Ashwin Shroff, Chairman & Managing Director, Excel Industries Ltd

Excel Industries Ltd, which has been a pioneer in the area of crop protection chemicals, has today emerged as one of the leading players in the specialty and performance chemicals catering to various industries such as agrochemicals, plastics, water treatment, additives, catalyst, pharma, etc. Excel is organised into two divisions - chemicals and environment & biotech – with chemicals contributing majorly to its overall turnover. While agro-still accounts for a major share of its chemicals division’s product portfolio, the company is reportedly planning for a big push in the pharma space. In this free-wheeling interview with Rakesh Rao, Ashwin Shroff, Chairman & Managing Director, Excel Industries Ltd, elaborates on the company’s future plans and strategy.
 
Of the two divisions, chemicals division has been a major contributor to Excel’s turnover. Do you see a change in this, with environment & biotech division contributing more in future?
I would not be overly worried about percentage; I want both to grow. Of the two, chemical is more matured business. On the other hand, waste management & biotech business is relatively new, and hence offer inherent growth opportunities. In chemicals, we are an established player and have got more credibility. Both the businesses should grow at robust rate. We are not going to put any artificial restriction on them. We see good potential in both.
 
How is the market evolving in India? Is China still posing threat to Indian companies?
India is one of leading players in the global industry with many companies exporting to the developed markets. In last 10-15 years, with imports becoming less costly with lowering of customs duties and other restrictions, imports from China to manufacture active (APIs) have increased. Pharma companies would buy from China and add value and sell and formulations. Most of the pharma companies sold their formulations in the local market, while exported bulk of APIs.
 
ALSO READ: Anand Sharma seeks greater market access for Indian pharma products in Russia

In last few years, Chinese currency Yuan has appreciated against the dollar. Also, the production cost has been increasing in China with the implementation of stringent regulations and escalating labour cost. Re has also lost against the dollar in recent past. All these factors will result in increase in cost of Chinese intermediates, making them uncompetitive compared with products manufactured in India. This will offer huge business opportunities to Indian companies in the intermediate space. This is where we see big potential market for us, and hence we are working this front.
 
Would you please elaborate on the strategy to tap the market?
We have been serving industry with commoditised in past. But now, we want to focus on advanced intermediates. We have put up a plant to manufacture these specialty chemicals. Most of our customers are exporters, hence we have to adhere to international standards. Keeping all these thing in mind, we have set up current Good Manufacturing Practices (cGMP) plant. With these specialty products, we are targeting areas such as antiretroviral, veterinary, etc.
 
The plant has been designed is such a way that it should be able to generate Rs 30-40 crore worth of business in foreseeable future. Once, we establish the business in advanced segment, it should contribute majorly to our turnover.
 
What is your vision for your company?
To be innovative and responsible company. Innovative in terms of new products, applications and processes. All the stakeholders (investors as well as employees, customers, community/society) should get equal treatment. Our vision is to grow at healthy rate with innovative products and be in tune with the requirements of the society and customers.

image
Business Standard
177 22
Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Chinese pharma intermediates may become uncompetitive compared to India: Ashwin Shroff, Excel Industries Ltd

Interview with Ashwin Shroff, Chairman & Managing Director, Excel Industries Ltd

Rakesh Rao  |  Mumbai 

Ashwin Shroff, CMD, Excel Industries

Excel Industries Ltd, which has been a pioneer in the area of crop protection chemicals, has today emerged as one of the leading players in the specialty and performance chemicals catering to various industries such as agrochemicals, plastics, water treatment, additives, catalyst, pharma, etc. Excel is organised into two divisions - chemicals and environment & biotech – with chemicals contributing majorly to its overall turnover. While agro-still accounts for a major share of its chemicals division’s product portfolio, the company is reportedly planning for a big push in the pharma space. In this free-wheeling interview with Rakesh Rao, Ashwin Shroff, Chairman & Managing Director, Excel Industries Ltd, elaborates on the company’s future plans and strategy.
 
Of the two divisions, chemicals division has been a major contributor to Excel’s turnover. Do you see a change in this, with environment & biotech division contributing more in future?


I would not be overly worried about percentage; I want both to grow. Of the two, chemical is more matured business. On the other hand, waste management & biotech business is relatively new, and hence offer inherent growth opportunities. In chemicals, we are an established player and have got more credibility. Both the businesses should grow at robust rate. We are not going to put any artificial restriction on them. We see good potential in both.
 
How is the market evolving in India? Is China still posing threat to Indian companies?
India is one of leading players in the global industry with many companies exporting to the developed markets. In last 10-15 years, with imports becoming less costly with lowering of customs duties and other restrictions, imports from China to manufacture active (APIs) have increased. Pharma companies would buy from China and add value and sell and formulations. Most of the pharma companies sold their formulations in the local market, while exported bulk of APIs.
 
ALSO READ: Anand Sharma seeks greater market access for Indian pharma products in Russia

In last few years, Chinese currency Yuan has appreciated against the dollar. Also, the production cost has been increasing in China with the implementation of stringent regulations and escalating labour cost. Re has also lost against the dollar in recent past. All these factors will result in increase in cost of Chinese intermediates, making them uncompetitive compared with products manufactured in India. This will offer huge business opportunities to Indian companies in the intermediate space. This is where we see big potential market for us, and hence we are working this front.
 
Would you please elaborate on the strategy to tap the market?
We have been serving industry with commoditised in past. But now, we want to focus on advanced intermediates. We have put up a plant to manufacture these specialty chemicals. Most of our customers are exporters, hence we have to adhere to international standards. Keeping all these thing in mind, we have set up current Good Manufacturing Practices (cGMP) plant. With these specialty products, we are targeting areas such as antiretroviral, veterinary, etc.
 
The plant has been designed is such a way that it should be able to generate Rs 30-40 crore worth of business in foreseeable future. Once, we establish the business in advanced segment, it should contribute majorly to our turnover.
 
What is your vision for your company?
To be innovative and responsible company. Innovative in terms of new products, applications and processes. All the stakeholders (investors as well as employees, customers, community/society) should get equal treatment. Our vision is to grow at healthy rate with innovative products and be in tune with the requirements of the society and customers.

RECOMMENDED FOR YOU

Chinese pharma intermediates may become uncompetitive compared to India: Ashwin Shroff, Excel Industries Ltd

Interview with Ashwin Shroff, Chairman & Managing Director, Excel Industries Ltd

Interview with Ashwin Shroff, Chairman & Managing Director, Excel Industries Ltd Excel Industries Ltd, which has been a pioneer in the area of crop protection chemicals, has today emerged as one of the leading players in the specialty and performance chemicals catering to various industries such as agrochemicals, plastics, water treatment, additives, catalyst, pharma, etc. Excel is organised into two divisions - chemicals and environment & biotech – with chemicals contributing majorly to its overall turnover. While agro-still accounts for a major share of its chemicals division’s product portfolio, the company is reportedly planning for a big push in the pharma space. In this free-wheeling interview with Rakesh Rao, Ashwin Shroff, Chairman & Managing Director, Excel Industries Ltd, elaborates on the company’s future plans and strategy.
 
Of the two divisions, chemicals division has been a major contributor to Excel’s turnover. Do you see a change in this, with environment & biotech division contributing more in future?
I would not be overly worried about percentage; I want both to grow. Of the two, chemical is more matured business. On the other hand, waste management & biotech business is relatively new, and hence offer inherent growth opportunities. In chemicals, we are an established player and have got more credibility. Both the businesses should grow at robust rate. We are not going to put any artificial restriction on them. We see good potential in both.
 
How is the market evolving in India? Is China still posing threat to Indian companies?
India is one of leading players in the global industry with many companies exporting to the developed markets. In last 10-15 years, with imports becoming less costly with lowering of customs duties and other restrictions, imports from China to manufacture active (APIs) have increased. Pharma companies would buy from China and add value and sell and formulations. Most of the pharma companies sold their formulations in the local market, while exported bulk of APIs.
 
ALSO READ: Anand Sharma seeks greater market access for Indian pharma products in Russia

In last few years, Chinese currency Yuan has appreciated against the dollar. Also, the production cost has been increasing in China with the implementation of stringent regulations and escalating labour cost. Re has also lost against the dollar in recent past. All these factors will result in increase in cost of Chinese intermediates, making them uncompetitive compared with products manufactured in India. This will offer huge business opportunities to Indian companies in the intermediate space. This is where we see big potential market for us, and hence we are working this front.
 
Would you please elaborate on the strategy to tap the market?
We have been serving industry with commoditised in past. But now, we want to focus on advanced intermediates. We have put up a plant to manufacture these specialty chemicals. Most of our customers are exporters, hence we have to adhere to international standards. Keeping all these thing in mind, we have set up current Good Manufacturing Practices (cGMP) plant. With these specialty products, we are targeting areas such as antiretroviral, veterinary, etc.
 
The plant has been designed is such a way that it should be able to generate Rs 30-40 crore worth of business in foreseeable future. Once, we establish the business in advanced segment, it should contribute majorly to our turnover.
 
What is your vision for your company?
To be innovative and responsible company. Innovative in terms of new products, applications and processes. All the stakeholders (investors as well as employees, customers, community/society) should get equal treatment. Our vision is to grow at healthy rate with innovative products and be in tune with the requirements of the society and customers.
image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard